2dOpinion
The therapy for the future
Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...
6d
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is ...
EXECUTIVE SUMMARYVial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE ...
Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...
HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today ...
Hello, and welcome to Wave Life Sciences 2025 Research Day. [Operator Instructions] Also, as a reminder, this conference is being recorded today. I will now turn the call over to Kate Rausch, Vice ...
The Senate Committee on Commerce, Science, and Transportation will host Alex Berenson, Sean Davis, Gene Kimmerman, and Eugene Volokh at a hearing on Wednesday, titled "Shut Your App: How Uncle Sam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback